跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
徐 之昇
副教授
,
國際生技醫療管理博士學位學程
合聘副教授
,
大數據科技及管理研究所
副教授
,
臺北醫學大學人工智慧醫療研究中心
https://orcid.org/0000-0003-2997-2404
電子郵件
jasonhsu
tmu.edu
tw
h-index
509
引文
14
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2013
2025
每年研究成果
概覽
指紋
網路
專案
(9)
研究成果
(68)
資料集
(2)
類似的個人檔案
(6)
指紋
查看啟用 Jason C. Hsu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Breast Cancer
70%
Antidiabetic Agent
46%
Non Small Cell Lung Cancer
46%
Clinical Research
41%
Cohort Study
40%
Disease
38%
Observational Study
31%
Adverse Event
31%
All Cause Mortality
30%
Febrile Neutropenia
29%
Chemotherapy
28%
Spine Fracture
27%
Drug Utilization
26%
Hip Fracture
26%
Cancer Survival
25%
Thiazolidinedione
25%
Immune Checkpoint Inhibitor
25%
Granulocyte Colony Stimulating Factor
25%
Sodium Glucose Cotransporter 2 Inhibitor
25%
Comorbidity
25%
Retrospective Study
22%
Anticarcinogen
21%
Erlotinib
21%
Pioglitazone
18%
Bisphosphonic Acid Derivative
18%
Rosiglitazone
18%
Epidermal Growth Factor Receptor
18%
Overall Survival
17%
Gefitinib
17%
Lung Cancer
16%
Cardiovascular Disease
15%
Combination Therapy
15%
Brain Ischemia
14%
Oral Antidiabetic Agent
14%
Population Study
14%
Prevalence
14%
Health Status
14%
Progression Free Survival
14%
Infection
13%
Heart Infarction
12%
Injury Severity
12%
Calcium Channel Blocker
12%
Prescription Medication
12%
Botulinum Toxin
12%
Proton Pump Inhibitor
12%
Community Pharmacy
12%
Implant
12%
Case-Control Study
12%
Dengue
12%
Medicine and Dentistry
Targeted Therapy
50%
Systematic Review
50%
Health Care Cost
48%
Breast Cancer
45%
Drug Therapy
45%
Time Series Analysis
41%
Cancer Therapy
40%
Antidiabetic Agent
37%
Clinical Research
34%
Malignant Neoplasm
30%
Disease
30%
Erlotinib
25%
Gefitinib
25%
COVID-19
25%
Network Meta-Analysis
25%
Meta-Analysis
25%
Lung Cancer Survival
25%
Sodium Glucose Cotransporter 2 Inhibitor
25%
Non Small Cell Lung Cancer
25%
Diabetes
23%
Cancer Diagnosis
20%
Logistic Regression Analysis
19%
Epidermal Growth Factor Receptor
18%
Odds Ratio
17%
Endoscopy
16%
Maturity Onset Diabetes of the Young
16%
Adverse Event
15%
Anticarcinogen
15%
Lung Cancer
14%
Patient Care
14%
Diabetes Mellitus
14%
Cancer Registry
14%
Infection
13%
Electronic Health Record
13%
Case-Control Study
12%
Biological Therapy
12%
Spastic Diplegia
12%
Osteoporosis
12%
Particle Therapy
12%
Microwave Thermotherapy
12%
Hypersalivation
12%
Degenerative Disease
12%
Tyrosine-Kinase Inhibitor
12%
Drug-Eluting Stent
12%
Implant
12%
Brain Ischemia
12%
Radiation Therapy
12%
Attitude
12%
Cancer Mortality
12%
Hepatocellular Carcinoma
12%
Nursing and Health Professions
Breast Cancer
52%
Cancer Therapy
26%
Drug Therapy
20%
Area under the Curve
20%
National Health Insurance
20%
Receiver Operating Characteristic
18%
Febrile Neutropenia
16%
Cancer Diagnosis
14%
Physician
14%
Cohort Analysis
13%
Time Series Analysis
13%
Reimbursement
13%
Hip Fracture
12%
Brain Ischemia
12%
Spine Fracture
12%
Drug Eluting Stent
12%
Systematic Review
12%
Cancer Survival
12%
Adverse Event
12%
Meta Analysis
12%
Heart Infarction
12%
Hypersalivation
12%
Infertility Therapy
12%
Bare Metal Stent
12%
Cerebral Palsy
12%
Empathy
12%
Cancer Screening
12%
Social Media
12%
Non Small Cell Lung Cancer
12%
Patient Care
12%
Botulinum Toxin
12%
Statin (Protein)
12%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
12%
Granulocyte Colony Stimulating Factor
12%
Teleconsultation
12%
Health Care Facility
12%
Public Hospital
12%
Thorax Pain
12%
Acute Heart Infarction
12%
Sodium Glucose Cotransporter 2 Inhibitor
12%
Logistic Regression Analysis
11%
Gefitinib
10%
Private Hospital
10%
Health Center
10%
Predictive Value
10%
Artificial Neural Network
9%
Botulinum Toxin A
9%
Erlotinib
8%
Comorbidity
8%
Emergency Ward
7%
